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ABSTRACT
The phosphoinositide 3-kinase (PI3K) family of signalling enzymes play a key role in the transduction of 
signals from activated cell surface receptors controlling cell growth and proliferation, survival, metabolism, 
and migration. The intracellular signalling pathway from activated receptors to PI3K and its downstream 
targets v-akt murine thymoma viral oncogene homolog (Akt) and mechanistic target of rapamycin 
(mTOR) is very frequently deregulated by genetic and epigenetic mechanisms in human cancer, including 
leukaemia and lymphoma. In the past decade, an arsenal of small molecule inhibitors of key enzymes in this 
pathway has been developed and evaluated in pre-clinical studies and clinical trials in cancer patients. These 
include pharmacological inhibitors of Akt, mTOR, and PI3K, some of which are approved for the treatment 
of leukaemia and lymphoma. The PI3K family comprises eight different catalytic isoforms in humans, 
which have been subdivided into three classes. Class I PI3K isoforms have been extensively studied in the 
context of human cancer, and the isoforms p110α and p110δ are validated drug targets. The recent approval 
of a p110δ-specific PI3K inhibitor (idelalisib/Zydelig®) for the treatment of selected B cell malignancies 
represents the first success in developing these molecules into anti-cancer drugs. In addition to PI3K 
inhibitors, mTOR inhibitors are intensively studied in leukaemia and lymphoma, and temsirolimus (Torisel®) 
is approved for the treatment of a type of lymphoma. Based on these promising results it is hoped that 
additional novel PI3K pathway inhibitors will in the near future be further developed into new drugs for 
leukaemia and lymphoma.
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INTRODUCTION
Leukaemia and Lymphoma
Leukaemia represents 3% of new cancer cases in 
males and females, while lymphoma represents 
5% and 4% of new cases in males and females, 
respectively.1 In terms of deaths, leukaemia accounts 
for 4% and 3% of total cancer deaths in males and 
females, respectively, while lymphoma accounts 
for 3% in both sexes.1 Leukaemia is subdivided 
into acute lymphocytic leukaemia (ALL), acute 
myeloid leukaemia (AML), chronic lymphocytic 
leukaemia (CLL), and chronic myeloid leukaemia 
(CML), for which different therapies are used and 
outcomes vary.2 Two main categories of lymphoma 
are Hodgkin’s lymphoma (HL) and non-Hodgkin’s 
lymphoma (NHL), the latter making up around 
90% of cases.3 However, lymphomas are currently 
classified depending on cell type, of which several 
types exist.4,5 The 2008 World Health Organization 
classification categorises the tumours of the 
haematopoietic and lymphoid tissues into: (i) 
mature B cell neoplasms; (ii) mature T cell and 
natural killer cell neoplasms; (iii) HL; (iv) histiocytic 
and dendritic cell neoplasms; and (v) post- 
transplant lymphoproliferative disorders.4,5 The 
management of haematological malignancies such 
as leukaemia and lymphoma has greatly benefited 
from the development of targeted anti-cancer 
therapies in the past decade.6,7 Successful s
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examples of targeted therapies include anti-
CD20 monoclonal antibodies (rituximab) in ALL 
and B cell lymphoma.7 Small molecule inhibitors 
(imatinib, Glivec®/Gleevec®) of the BCR-ABL kinase 
(breakpoint cluster region-Abelson murine 
leukaemia viral oncogene homolog) have been 
successfully applied to the treatment of CML. The 
hyper-activation of the phosphoinositide 3-kinase/
v-akt murine thymoma viral oncogene homolog/
mechanistic target of rapamycin (PI3K/Akt/mTOR) 
pathway has been linked to increased cell growth 
and proliferation, survival, and chemoresistance 
in leukaemia and lymphoma, and thus also 
represents an attractive target for the development 
of anti-cancer drugs in these malignancies.8-12
The PI3K Signalling Pathway
PI3Ks are a family of lipid kinases 
that catalyse the phosphorylation of plasma 
membrane phosphoinositides on the D-3 
position of the inositol ring, resulting in the 
production of three distinct second messengers: 
phosphatidylinositol 3-monophosphate (PI(3)P), 
phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), 
and phosphatidylinositol 3,4,5-trisphosphate (PI 
(3,4,5)P3/PIP3).
13 PIP3 is the key second messenger 
in the activation of the PI3K downstream targets 
Akt and mTOR. In short, PIP3 binding to the 
pleckstrin homology domains of Akt and 
phosphoinositide-dependent protein kinase-1 
(PDK1) results in full activation of Akt, through 
phosphorylation at Thr308 by PDK1 and at Ser473 
by the mechanistic target of rapamycin complex 
2 (mTORC2) (Figure 1).8,9,12 Active Akt then 
phosphorylates an array of proteins that control 
cell survival, growth, and cell cycle progression.8,9,12 
These include glycogen synthase kinase-3, 
forkhead box, subgroup O transcription factors, 
apoptosis-modulating proteins of the Bcl-2 
family, and the murine double minute-2 E3 
ubiquitin protein ligase (Figure 1).8,9,12 Akt-mediated 
phosphorylation of the tuberous sclerosis-2 
(TSC2) protein impairs the GTPase-activating 
activity of the TSC1/TSC2 complex towards the rat 
sarcoma (Ras) homologue enriched in the brain 
(Rheb). Rheb activates the mechanistic target 
of rapamycin complex 1 (mTORC1), which in turn 
controls cell growth via the ribosomal protein S6 
kinase and eukaryotic translation initiation factor 
4E binding protein (Figure 1).8,9,12 Based on primary 
sequence homology, regulation, and in vitro 
substrate specificity, PI3Ks are subdivided into 
three classes (I-III).12,14 Class I PI3Ks are further 
subdivided into Class IA and IB, based on the type 
of cell surface receptor that activates PI3Ks: 
Class IA PI3Ks (comprising the catalytic isoforms 
p110α, p110β, and p110δ) are activated by receptor 
tyrosine kinases (RTKs), while the Class IB PI3Ks 
(comprising the catalytic isoform p110γ) are 
activated by G protein-coupled receptors. Class I 
PI3Ks can also be activated by direct binding of 
Ras to the p110 catalytic isoforms.8,9,12
Deregulation of PI3K/Akt/mTOR Signalling  
in Cancer
Constitutive activation of the PI3K/Akt/mTOR 
pathway has been reported in many different 
human cancers and has been linked to 
different types of molecular alterations.15 Somatic 
mutations can target the genes encoding catalytic 
PI3K isoforms (mostly PIK3CA-encoding p110α) 
or regulatory isoforms (mostly PIK3R1-encoding 
p85α). PIK3CA mutations are clustered in two 
‘hot spots’ located in the helical (exon 9) and 
kinase (exon 20) domains and are associated 
with increased kinase activity and oncogenic 
potential.16,17 Intriguingly, somatic mutations that 
activate catalytic Class I PI3K isoforms are mostly 
restricted to PIK3CA, and the genes encoding the 
other Class I catalytic isoforms, such as PIK3CB, 
PIK3CD, and PIK3CG have not been found to 
be targeted by the same ‘hot spot’ mutations in 
cancer.16 However, it should be noted that p110β, 
p110δ, and p110γ have the ability to induce oncogenic 
transformation as wild-type proteins.18 Somatic 
mutations found in cancer can also target the 
genes encoding Akt isoforms and mTOR. Another 
type of genetic alteration targeting components 
and regulators of the PI3K/Akt/mTOR pathway 
are mutations in the phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN).15 PTEN 
is a phosphatase that de-phosphorylates PIP3 to 
produce phosphatidylinositol 4,5-bisphosphate (PI 
(4,5)P2), thus antagonising PI3K activity. PTEN 
regulation is complex and involves a variety of 
transcriptional and post-transcriptional events 
that can impact on its expression and activity.19 In 
addition, the PI3K/Akt/mTOR pathway can be 
activated in cancer by mutations in RTK or RAS 
genes, RTK hyperactivation driven by receptor 
over-expression/amplification, or the establishment 
of autocrine loops involving RTKs and their 
cognate ligand.
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PI3K/Akt/mTOR Signalling in Leukaemia  
and Lymphoma
Similarly to the situation in other cancers, 
deregulated activation of the PI3K/Akt/mTOR 
pathway has been reported in leukaemia and 
lymphoma.9,11,12,20 In general, PIK3CA mutations are 
not believed to be the major cause of PI3K/
Akt/mTOR pathway activation in leukaemia and 
lymphoma.21 In contrast, PTEN inactivation has been 
reported in AML and NHL.22,23 In addition, mutations 
and hyperactivation of tyrosine kinases (BCR-
ABL), Feline McDonough Sarcoma-like tyrosine 
kinase 3, mast/stem cell growth factor receptor, 
platelet-derived growth factor receptor-β, or 
Ras (NRAS and KRAS), as well as increased 
expression/activity of components of the pathway 
can be the underlying factors.8,9,24,25  
PI3K/Akt/mTOR Pathway Inhibitors as  
Anti-Cancer Drugs
Over 20 years after the discovery of the first 
pharmacological inhibitors of PI3K and mTOR, a 
wide array of small molecules has been developed 
by the pharmaceutical industry.13,14,26,27 These can 
be broadly subdivided into different classes: 
pan-PI3K inhibitors (BKM-120), isoform-specific 
PI3K inhibitors (idelalisib, IPI-145), PI3K/mTOR 
inhibitors (BEZ-235, VS-5584), Akt inhibitors 
(MK-2206, perifosine), allosteric mTOR inhibitors 
(rapamycin analogs, rapalogs: sirolimus, everolimus, 
temsirolimus, ridaforolimus), and mTOR kinase 
inhibitors (OSI-027, CC-223) (Figure 1 and Figure 2). 
Generally, single agent PI3K/Akt/mTOR pathway 
inhibitor treatment has been reported to produce 
only incomplete responses in different cancers27 
and the genetic background of the tumours, in 
particular the PIK3CA mutational status, is believed 
to play a major role in the response to these 
agents.28 However, combining these agents with 
standard chemotherapy or other targeted agents 
may represent a more promising approach to 
successful use of these agents in human 
cancer patients.27 
PI3K/Akt/mTOR Pathway Inhibitors in 
Leukaemia and Lymphoma
In contrast to the situation in other cancers, B cell 
malignancies appear to be uniquely responsive 
to PI3K inhibitors, in particular to isoform-specific 
PI3K inhibitors targeting the Class IA isoform 
p110δ.14,27,29-31 This PI3K isoform is hallmarked by 
its tissue specificity, since it is mostly expressed in 
leukocytes and plays a crucial role in intracellular 
signalling by the B and T cell receptors.32-34 Although 
it is not targeted by somatic mutations in 
cancer, its expression and activity was reported to 
be increased in leukaemia and linked to 
cell proliferation and chemoresistance.14,35-37 
Accordingly, small molecule inhibitors of p110δ 
(Figure 1 and Figure 2), in particular CAL-101 
(idelalisib, Zydelig®) were shown to be active 
in several pre-clinical models of leukaemia and 
lymphoma.14,36,38-41 The pre-clinical data for CAL-101 
in leukaemia and lymphoma and the early phase 
clinical studies have been recently reviewed.14,41 
Pre-clinical studies of CAL-101 in CLL showed 
that the p110δ inhibitor induced apoptosis in 
primary cells ex vivo.40 CAL-101 was also 
reported to induce apoptosis in lymphoma cell 
lines and primary cells.38 The subsequent clinical 
trials with idelalisib led to its approval by the 
FDA in July 2014 for relapsed CLL (in combination 
with rituximab), for relapsed follicular B cell NHL, 
and for relapsed small lymphocytic leukaemia.29,30,42 
In a Phase I trial in relapsed/refractory CLL, 
idelalisib showed a favourable safety profile, while 
inducing an overall response rate (ORR) of 72%.43 
The Phase III study of idelalisib and rituximab 
in CLL patients demonstrated improved rates 
of overall response and overall survival at 12 
months, compared to rituximab and placebo.29 In 
a Phase I study in relapsed indolent NHL, 
idelalisib was reported to have a favourable 
safety profile and achieved an ORR of 47%.44 
Another Phase I study in relapsed/refractory 
mantle cell lymphoma also reported a favourable 
safety profile and an ORR of 40% for idelalisib.45 
The Phase II study of idelalisib in patients with NHL 
(follicular lymphoma, small lymphocytic lymphoma, 
marginal-zone lymphoma, and lymphoplasmacytic 
lymphoma with or without Waldenstrom’s 
macroglobulinaemia), showed a response rate of 
57%, with 6% of patients having complete 
responses.30 Idelalisib also showed an acceptable 
safety profile in NHL patients in this study.30 
Idelalisib is currently undergoing further clinical 
testing in additional indications, as single agent or 
in combination with other drugs (Table 1). 
In addition to CAL-101, other PI3K inhibitors are 
currently under study in leukaemia and lymphoma. 
IPI-145, a dual specificity p110δ and p110γ inhibitor, 
was shown to be active in pre-clinical studies in 
CLL.46 This compound is currently being evaluated 
in clinical trials in lymphoma (Phase III in 
combination with rituximab) and CLL (Phase III 
in combination with the anti-CD20 monoclonal 
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antibody ofatumumab) (Table 1). BKM-120 is a pan-
class I PI3K inhibitor which is currently undergoing 
clinical testing in different cancers. This inhibitor 
was reported to be active in pre-clinical studies in 
B cell lymphoma and CLL.47-49 BKM-120 is currently 
undergoing Phase I and Phase II clinical testing 
in leukaemia and lymphoma (Table 1).
Another approach to target the PI3K/Akt/mTOR 
pathway in haematological cancers is to use dual 
specificity PI3K/mTOR inhibitors, such as BEZ-
235 and VS-5584 (Figure 1 and Figure 2). BEZ-
235 was reported to have pre-clinical activity in 
AML and lymphoma.50-52 BEZ235 and VS-5584 
are currently undergoing Phase I clinical testing 
in leukaemia (Table 1). The rapamycin analogs 
(‘rapalogs’) are allosteric inhibitors of mTOR and 
only inhibit mTORC1, while mTORC2 is resistant 
to these compounds. Rapalogs represent the 
class of inhibitors of the PI3K/Akt/mTOR pathway 
which are the subject of the greatest number 
of clinical trials at present (Table 1). The clinical 
studies underway in leukaemia and lymphoma 
are investigating rapalogs (sirolimus, everolimus, 
temsirolimus, ridaforolimus) as single agents, or 
in combination with standard chemotherapeutic 
agents, or other targeted agents (Table 1). 
Figure 1: Schematic representation of the PI3K pathway, its regulation by growth factor (GF) binding to 
receptor tyrosine kinases (RTKs) and the main downstream mediators activated. 
The main classes of targeted drugs (Akt inhibitors, PI3K inhibitors, PI3K/mTOR inhibitors, mTOR kinase 
inhibitors, and allosteric mTOR inhibitors/rapalogs) are also depicted. 
PI3K: phosphoinositide 3-kinase; mTOR: mechanistic target of rapamycin; Akt: murine thymoma viral 
oncogene homolog; mTORC1: rapamycin complex 1; mTORC2: rapamycin complex 2; Rheb: Ras homologue 
enriched in the brain; 4E-BP: 4E binding protein; S6K: S6 kinase; SOS: son of sevenless; GRB2: growth 
factor receptor-bound protein 2; SHC: SH2-containing proteins; ERK: extracellular-signal-regulated 
kinase; Ras: rat sarcoma; MEK: mitogen-activated protein kinase; FOXO: forkhead box subgroup O; GSK3: 
glycogen synthase kinase 3; BAD: Bcl-2-associated death promoter; TSC1/2: tuberous sclerosis complex 
Type 1/2; PDK1: phosphoinositide-dependent kinase-1.
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Temsirolimus (Torisel®) is approved for the 
treatment of relapsed and/or refractory mantle 
cell lymphoma (MCL) in the European Union and 
several other countries outside the USA. In a 
Phase III trial, temsirolimus significantly improved 
progression-free survival and objective response 
rate compared with other therapeutic regimens 
in patients with relapsed or refractory MCL.53 In a 
Phase II trial in relapsed or refractory MCL, the 
combination of temsirolimus and rituximab 
produced an ORR of 59%.54 Everolimus was also 
found to be active in relapsed or refractory MCL in 
a Phase II clinical trial.55
In addition to rapalogs, mTOR can be targeted 
by kinase inhibitors that have the advantage of 
inhibiting both mTORC1 and mTORC2. The mTOR 
kinase inhibitor OSI-027 was reported to be active 
in pre-clinical studies in BCR-ABL-expressing CML 
cells, AML, ALL, and lymphoma.56-58 OSI-027 and 
CC223 are currently undergoing Phase I clinical 
testing in lymphoma, together with other solid 
tumours (Table 1). The Akt inhibitor MK-2206 was 
evaluated in a Phase II clinical trial in AML, but had 
only limited activity as a single agent, although it 
displayed anti-leukemic activity in a pre-clinical 
setting.59 Further clinical trials are ongoing with 
this agent in lymphoma and leukaemia (Table 1). 
Perifosine is another Akt inhibitor that has been 
evaluated in pre-clinical and clinical studies in 
leukaemia and lymphoma.60-62 A Phase II study 
in CLL found limited responses, but these did not 
correlate with impaired Akt phosphorylation, 
suggesting Akt-independent effects of perifosine.63 
Feedback and feedforward loops are known to 
occur between PI3K, mTORC1, mTORC2, and Akt. 
Figure 2: Chemical structures of selected PI3K/Akt/mTOR pathway inhibitors. 
The p110δ inhibitor CAL-101 (idelalisib), the PI3K/mTOR inhibitor BEZ-235, the Akt inhibitors MK-2206 and 
perifosine, as well as the mTOR inhibitors OSI-027 and rapamycin are presented.
PI3K: phosphoinositide 3-kinase; Akt: v-akt murine thymoma viral oncogene homolog; mTOR: mechanistic 
target of rapamycin.
MK-2206
OSI-027 Rapamycin
Perifosine
BEZ-235
CAL-101(idelalisib)
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ID  
ClinicalTrials.gov
Phase Drug(s) Target(s) Disease
NCT01756118 I BEZ-235 single agent PI3K + mTOR acute leukaemia
NCT01991938 I VS-5584 single agent PI3K + mTOR lymphoma
NCT01396499 I BKM-120 single agent Class I PI3K leukaemia
NCT02049541 I BKM-120 + rituximab Class I PI3K B cell lymphoma
NCT01719250 pilot study BKM-120 single agent Class I PI3K NHL
NCT01693614 II BKM-120 single agent Class I PI3K lymphoma
NCT01476657 I IPI-145 single agent p110δ + p110γ HM
NCT01871675 I IPI-145 + bendamustine/rituximab p110δ + p110γ lymphoma, CLL
NCT02158091 Ib/II IPI-145 + fludarabine/cyclophospha-
mide/rituximab
p110δ + p110γ CLL
NCT01882803 II IPI-145 single agent p110δ + p110γ NHL
NCT02049515 III IPI-145 + ofatumumab p110δ + p110γ CLL, SLL
NCT02004522 III IPI-145 + ofatumumab p110δ + p110γ CLL, SLL
NCT02204982 III IPI-145 + rituximab p110δ + p110γ lymphoma
NCT01088048 I idelalisib + chemotherapy/immunomod-
ulatory/anti-CD20
p110δ lymphoma, CLL
NCT01090414 I idelalisib single agent p110δ CLL, NHL
NCT01644799 I idelalisib + lenalidomide p110δ follicular lymphoma
NCT01306643 I/II idelalisib single agent p110δ NHL
NCT01838434 I/II idelalisib + lenalidomide p110δ lymphoma (MCL)
NCT01393106 II idelalisib single agent p110δ HL
NCT01203930 II idelalisib + rituximab p110δ CLL, SLL
NCT01796470 II idelalisib + GS-9973 p110δ lymphoma, CLL
NCT02135133 II idelalisib + ofatumumab p110δ CLL, SLL
NCT02044822 II idelalisib + rituximab p110δ CLL (17p del)
NCT01569295 III idelalisib + bendamustine/rituximab p110δ CLL
NCT01539291 III idelalisib single agent p110δ CLL
NCT01732926 III idelalisib + bendamustine/rituximab p110δ NHL
NCT01732913 III idelalisib + rituximab p110δ NHL
NCT01659021 III idelalisib + ofatumumab p110δ CLL
NCT01980888 III idelalisib + bendamustine/rituximab p110δ CLL
NCT01658007 pilot study sirolimus + multiagent chemotherapy mTOR leukaemia, lymphoma
NCT00874562 rapamycin + corticosteroid mTOR ALL
NCT01154439 I everolimus + multiagent chemotherapy mTOR leukaemia
NCT01403415 I temsirolimus + dexamethasone/ mitox-
antrone/vinc/pegaspargase
mTOR leukaemia/lymphoma
NCT01523977 I everolimus + chemotherapy mTOR paediatric ALL
NCT00671112 I everolimus + bortezomib mTOR lymphoma
NCT02240719 I everolimus + bendamustine mTOR leukaemia, lymphoma
NCT00819546 I everolimus + PKC412 mTOR AML, MDS
NCT01902160 I temsirolimus + brentuximab vedotin mTOR HL
NCT01535989 I temsirolimus + inotuzumab ozogamicin mTOR B cell lymphoma
NCT01169532 I ridaforolimus + vorinostat mTOR lymphoma
Table 1: Overview of current clinical trials with selected PI3K/Akt/mTOR pathway inhibitors in leukaemia 
and lymphoma (data from http://clinicaltrials.gov/). 
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mTOR: mechanistic target of rapamycin; PI3K: phosphoinositide 3-kinase; NHL: non-Hodgkin’s 
lymphoma; CLL: chronic lymphocytic leukaemia; MCL: mantle cell lymphoma; ALL: acute lymphocytic 
leukaemia; HL: Hodgkin’s lymphoma; Akt: v-akt murine thymoma viral oncogene homolog; SLL: small 
lymphocytic leukaemia; MDS: myelodysplastic syndrome; HM: haematological malignancy; CNS: central 
nervous system; AML: acute myeloid leukaemia.
Table 1 continued.
ID  
ClinicalTrials.gov
Phase Drug(s) Target(s) Disease
NCT00968253 I,II everolimus + chemotherapy mTOR ALL
NCT00935792 I,II everolimus + alemtuzumab mTOR lymphocytic leukaemia
NCT00918333 I,II everolimus + panobinostat mTOR leukaemia, lymphoma
NCT02109744 I,II rapamycin + decitabine mTOR AML
NCT01075321 I,II everolimus + lenalidomide mTOR lymphoma
NCT01076543 I,II temsirolimus + lenalidomide mTOR lymphoma
NCT01381692 I,II temsirolimus + bortezomib/rituximab/
dexamethasone
mTOR lymphoma
NCT01389427 I,II temsirolimus + rituximab/chemotherapy mTOR MCL
NCT01198665 I,II everolimus + chemotherapy mTOR lymphoma
NCT01567475 I,II everolimus + rituximab mTOR NHL
NCT01078142 I,II temsirolimus + rituximab, bendamustine mTOR lymphoma
NCT00474929 I,II everolimus + sorafenib mTOR lymphoma
NCT01453504 I,II everolimus + DHAP mTOR HL
NCT01854606 Ib/II everolimus + AEB071 mTOR B cell lymphoma
NCT00634244 II sirolimus + combination chemotherapy mTOR AML
NCT01611116 II temsirolimus + standard therapy mTOR AML
NCT01869114 II sirolimus + azacitidine mTOR AML, MDS
NCT00838955 II temsirolimus single agent mTOR HL
NCT01022996 II everolimus single agent mTOR HL
NCT01843998 II sirolimus single agent mTOR cut T cell lymphoma
NCT01665768 II everolimus + rituximab mTOR lymphoma
NCT01653067 II temsirolimus + rituximab, DHAP mTOR B cell lymphoma
NCT00942747 II temsirolimus single agent mTOR lymphoma (CNS)
NCT01637090 II everolimus single agent mTOR cut T cell lymphoma
NCT01281917 II temsirolimus + velcade mTOR NHL
NCT00978432 II everolimus + LBH589 mTOR B cell lymphoma
NCT00790036 III everolimus single agent mTOR B cell lymphoma
NCT01646021 III temsirolimus (versus ibrutinib) single 
agent
mTOR MCL
NCT00700258 IV temsirolimus + sunitinib mTOR MCL
NCT01180049 IV temsirolimus single agent mTOR NHL
NCT00698243 I OSI-027 single agent mTOR lymphoma (+ other) 
NCT01177397 I,II CC-223 single agent mTOR B cell lymphoma
NCT01369849 I/II MK-2206 + bendamustine/rituximab Akt CLL, SLL
NCT01258998 II MK-2206 single agent Akt lymphoma
NCT01253447 II MK-2206 single agent Akt AML
NCT01481129 II MK-2206 single agent Akt B cell lymphoma
 ONCOLOGY  •  March 2015   EMJ  EUROPEAN MEDICAL JOURNAL  ONCOLOGY  •  March 2015   EMJ  EUROPEAN MEDICAL JOURNAL 56 57
These loops explain that synergy between selected 
kinase inhibitors (such as JAK2 inhibitors) and PI3K 
inhibitors, especially pan-class I PI3K inhibitors, 
has been reported in myeloid malignancies, 
including myeloproliferative neoplasms.64,65 These 
combinations may be further studied in other 
haematological malignancies, where these 
regulatory loops are relevant.
CONCLUSION AND OUTLOOK
The approval of the first PI3K inhibitor for CLL 
and B cell NHL in 2014 strongly supports the 
further development of PI3K pathway inhibitors 
in leukaemia and lymphoma. The most advanced 
drugs are p110δ PI3K inhibitors (idelalisib) and 
rapalogs (temsirolimus). Multiple clinical trials are 
underway with these agents in haematological 
malignancies and it is likely that further drugs 
will be approved in different indications in the 
near future. There are different possible ways 
to optimise the use of these agents in the 
future, including the development of predictive 
biomarkers for patient selection, the design of 
additional combinatorial approaches involving 
PI3K inhibitors and other drugs (targeted agents 
or standard chemotherapy), and the elucidation 
of potential mechanisms of resistance.
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